These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

688 related items for PubMed ID: 30813769

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study.
    Takeshima T, Sakai F, Hirata K, Imai N, Matsumori Y, Yoshida R, Peng C, Cheng S, Mikol DD.
    Headache; 2021 Jun; 61(6):927-935. PubMed ID: 34153117
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review.
    Urits I, Jones MR, Gress K, Charipova K, Fiocchi J, Kaye AD, Viswanath O.
    Curr Pain Headache Rep; 2019 Mar 14; 23(5):29. PubMed ID: 30874961
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Calcitonin Gene-Related Peptide Antagonists for the Prevention of Migraine: Highlights From Pivotal Studies and the Clinical Relevance of This New Drug Class.
    Arca K, Reynolds J, Sands KA, Shiue HJ.
    Ann Pharmacother; 2020 Aug 14; 54(8):795-803. PubMed ID: 32019317
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Erenumab patient characteristics, medication adherence, and treatment patterns in the United States.
    Hines DM, Shah S, Multani JK, Wade RL, Buse DC, Bensink M.
    Headache; 2021 Apr 14; 61(4):590-602. PubMed ID: 33594672
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Phase I, Randomized, Double-blind, Placebo-controlled, Single-dose, and Multiple-dose Studies of Erenumab in Healthy Subjects and Patients With Migraine.
    de Hoon J, Van Hecken A, Vandermeulen C, Yan L, Smith B, Chen JS, Bautista E, Hamilton L, Waksman J, Vu T, Vargas G.
    Clin Pharmacol Ther; 2018 May 14; 103(5):815-825. PubMed ID: 28736918
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.